This is markedly lower than was seen in early trials of PD-1 inhibitors for Hodgkin’s lymphoma where >65% of patients had a response to treatment and 17–21% achieved a complete response [30, 31], but more consistent with response rates in previously treated patients with melanoma (28%), NSCLC (18%), and renal cell carcinoma (27%) [32]. The gene discussed is PDCD1; the disease is melanoma.